BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• 

  Drug Development

  AI Return on Investment: Just Because We Can, Should We?

  In this episode, Lori and guests continue their exploratory discussion on AI and focus on the challenges of globalization and return on investment.

  September 26, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Multiple sclerosis

  Study Casts Doubt on Benefit of Anti-CD20 Therapies in Multiple Sclerosis

  New research has found that MS patients treated with anti-CD20 antibodies, such as Roche’s Ocrevus, do not experience significantly slower progression of disability.

  September 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics

  A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.

  September 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  Telling the Right Story: Overselling, Underselling Can Hurt Your Candidacy

  During the job application and interview process, candidates who lie to prospective employers and those who don’t properly highlight their accomplishments can find it difficult to land—or keep—their next role. We asked experts how to sell yourself positively and honestly.

  September 26, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Collaboration

  Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to Expand Pipeline

  While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.

  September 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Venture capital

  ARCH Fuels Up With $3B to Support Next Class of AI Biotechs

  ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to support new startups working with AI.

  September 26, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Sickle cell disease

  Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death

  Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in patients with sickle cell disease. Guggenheim Securities analysts said the setback increases investor frustrations with the company’s business development track record.

  September 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Microbix Presenting at Muskoka Capital Conference

  September 26, 2024

   · 

  4 min read
• Press Releases

  Atavistik Bio Appoints Oncology Clinical Development Leader Mohammad Hirmand, M.D. to Board of Directors

  September 26, 2024

   · 

  2 min read
• Press Releases

  OncoC4 and AcroImmune Announce Merger

  September 26, 2024

   · 

  5 min read